IL233266A0 - Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone - Google Patents

Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone

Info

Publication number
IL233266A0
IL233266A0 IL233266A IL23326614A IL233266A0 IL 233266 A0 IL233266 A0 IL 233266A0 IL 233266 A IL233266 A IL 233266A IL 23326614 A IL23326614 A IL 23326614A IL 233266 A0 IL233266 A0 IL 233266A0
Authority
IL
Israel
Prior art keywords
methylnaltrexone
prevention
treatment
methods
oral compositions
Prior art date
Application number
IL233266A
Other languages
English (en)
Hebrew (he)
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of IL233266A0 publication Critical patent/IL233266A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL233266A 2011-12-19 2014-06-19 Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone IL233266A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577654P 2011-12-19 2011-12-19
PCT/US2012/070612 WO2013096444A1 (en) 2011-12-19 2012-12-19 Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone

Publications (1)

Publication Number Publication Date
IL233266A0 true IL233266A0 (en) 2014-08-31

Family

ID=48669445

Family Applications (1)

Application Number Title Priority Date Filing Date
IL233266A IL233266A0 (en) 2011-12-19 2014-06-19 Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone

Country Status (11)

Country Link
US (2) US20130317050A1 (enExample)
EP (1) EP2793888A4 (enExample)
JP (2) JP2015501849A (enExample)
KR (1) KR20140107540A (enExample)
CN (2) CN104254332A (enExample)
AU (3) AU2012359013A1 (enExample)
BR (1) BR112014014805A2 (enExample)
CA (1) CA2859203C (enExample)
IL (1) IL233266A0 (enExample)
MX (1) MX2014007312A (enExample)
WO (1) WO2013096444A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
WO2016061531A1 (en) * 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
JP2019513355A (ja) * 2016-03-29 2019-05-30 コロナリーコンセプツ エルエルシー 便秘症を処置するための製剤
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS601128A (ja) * 1983-06-15 1985-01-07 Shionogi & Co Ltd 作用持続型セフアクロル製剤
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP1494683A1 (en) * 2002-04-05 2005-01-12 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
US20070010543A1 (en) * 2005-07-01 2007-01-11 Dynogen Pharmaceuticals, Inc. Compositions and methods for treating gastrointestinal hypomotility and associated disorders
EA201001643A1 (ru) * 2008-05-07 2011-06-30 Нектар Терапеутикс Пероральное введение периферически действующих опиоидных антагонистов
CN101845047B (zh) * 2009-12-31 2011-12-07 南京臣功制药有限公司 一种溴甲基纳曲酮的制备方法
SG10201501821RA (en) * 2010-03-11 2015-05-28 Wyeth Llc Oral formulations and lipophilic salts of methylnaltrexone

Also Published As

Publication number Publication date
CA2859203A1 (en) 2013-06-27
CN104254332A (zh) 2014-12-31
US20130317050A1 (en) 2013-11-28
AU2019203694A1 (en) 2019-06-20
BR112014014805A2 (pt) 2017-06-13
MX2014007312A (es) 2014-08-27
US20190231771A1 (en) 2019-08-01
EP2793888A1 (en) 2014-10-29
AU2012359013A1 (en) 2014-06-26
KR20140107540A (ko) 2014-09-04
AU2017258808A1 (en) 2017-11-23
JP2019048820A (ja) 2019-03-28
JP2015501849A (ja) 2015-01-19
CA2859203C (en) 2020-08-25
CN110384701A (zh) 2019-10-29
NZ625863A (en) 2016-11-25
EP2793888A4 (en) 2015-10-28
WO2013096444A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
AP3155A (en) Methods of administering pirfenidone therapy
TWI562775B (en) Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
IL230528B (en) An abuse-resistant pharmaceutical preparation for the treatment of opioid addiction
ZA201109334B (en) Dosage forms of apixaban
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
EP2564847A4 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVING PRASUGREL SOLUBILITY AND PREPARATION METHOD THEREOF
EP2440220A4 (en) COMPOSITIONS AND METHOD FOR PREPARING COMPOSITIONS FOR PREVENTING AND TREATING HYPERTENSION
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
ZA201304694B (en) Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
IL214455A0 (en) Methods and compositions for treatment of neovascularization
IL216993A0 (en) Compositions and methods for treatment of multiple sclerosis
GB2495885B (en) Combination pharmaceutical composition and methods of treating genitourinary system disorders
IL222841B (en) Cadherin-11 antagonist for the treatment of leprosy
IL233266A0 (en) Methods for the treatment and prevention of opioid-induced constipation using oral compositions of methylnaltrexone
EP2670243A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLAUCOMA
IL215054A0 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
HK1203373A1 (en) Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
EP2640468A4 (en) ADMINISTRATIVE AND TREATMENT PROCEDURES
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
GB201118196D0 (en) Compositions and methods for selective prevention of mRNA translation
IL220796A0 (en) Compositions and methods for treating gliblastoma gbm
ZA201107399B (en) Method and compositions for treatment of cancer